These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 20470758)
1. Targeted therapy of chronic myeloid leukemia. Sullivan C; Peng C; Chen Y; Li D; Li S Biochem Pharmacol; 2010 Sep; 80(5):584-91. PubMed ID: 20470758 [TBL] [Abstract][Full Text] [Related]
2. The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. Chen Y; Li D; Li S Cell Cycle; 2009 Nov; 8(21):3488-92. PubMed ID: 19823023 [TBL] [Abstract][Full Text] [Related]
3. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Chen Y; Peng C; Sullivan C; Li D; Li S Leukemia; 2010 Sep; 24(9):1545-54. PubMed ID: 20574455 [TBL] [Abstract][Full Text] [Related]
4. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437 [TBL] [Abstract][Full Text] [Related]
6. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147 [TBL] [Abstract][Full Text] [Related]
7. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012 [TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Chen Y; Peng C; Sullivan C; Li D; Li S Anticancer Agents Med Chem; 2010 Feb; 10(2):111-5. PubMed ID: 20184539 [TBL] [Abstract][Full Text] [Related]
10. Induction of Chronic Myeloid Leukemia in Mice. Zhang H; Li S Methods Mol Biol; 2016; 1465():17-25. PubMed ID: 27581135 [TBL] [Abstract][Full Text] [Related]
11. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034 [TBL] [Abstract][Full Text] [Related]
12. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Hu Y; Chen Y; Douglas L; Li S Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703 [TBL] [Abstract][Full Text] [Related]
14. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia]. Buchdunger E Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067 [TBL] [Abstract][Full Text] [Related]
15. Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. Sadovnik I; Hoelbl-Kovacic A; Herrmann H; Eisenwort G; Cerny-Reiterer S; Warsch W; Hoermann G; Greiner G; Blatt K; Peter B; Stefanzl G; Berger D; Bilban M; Herndlhofer S; Sill H; Sperr WR; Streubel B; Mannhalter C; Holyoake TL; Sexl V; Valent P Clin Cancer Res; 2016 Apr; 22(8):2051-61. PubMed ID: 26607600 [TBL] [Abstract][Full Text] [Related]
16. Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib. Jin Y; Yao Y; Chen L; Zhu X; Jin B; Shen Y; Li J; Du X; Lu Y; Jiang S; Pan J Theranostics; 2016; 6(11):1947-62. PubMed ID: 27570562 [TBL] [Abstract][Full Text] [Related]
17. Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells. Liu C; Nie D; Li J; Du X; Lu Y; Li Y; Zhou J; Jin Y; Pan J Cancer Res; 2018 Mar; 78(6):1522-1536. PubMed ID: 29321163 [TBL] [Abstract][Full Text] [Related]
18. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Chen Y; Hu Y; Zhang H; Peng C; Li S Nat Genet; 2009 Jul; 41(7):783-92. PubMed ID: 19503090 [TBL] [Abstract][Full Text] [Related]
19. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis. Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443 [TBL] [Abstract][Full Text] [Related]
20. Chronic myelogenous leukemia: from molecular biology to clinical aspects and novel targeted therapies. Inokuchi K J Nippon Med Sch; 2006 Aug; 73(4):178-92. PubMed ID: 16936444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]